NAD+ ⇒ Nicotinamide riboside augments the human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammator

[Drdavid]

Nicotinamide riboside augments the human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures in aged subjects: a placebo-controlled, randomized trial

Yasir S Elhassan, Katarina Kluckova, Rachel S Fletcher, Mark Schmidt, Antje Garten, Craig L Doig, David M Cartwright, Lucy Oakey, Claire V Burley, Ned Jenkinson, Martin Wilson, Samuel J E Lucas, Ildem Akerman, Alex Seabright, Yu-Chiang Lai, Daniel A Tennant, Peter Nightingale, Gareth A Wallis, Konstantinos N Manolopoulos, View ORCID ProfileCharles Brenner, Andrew Philp, Gareth G Lavery
doi: https://doi.org/10.1101/680462

This study evaluated the effect of Nicotinamide Riboside on 12 aged men over a 21 day period in a placebo-controlled, randomized, double-blind, crossover trial. The study used 1 gram of Nicotinamide Riboside per day divided into 2 equal doses in one group and a placebo of 1 gram per day divided into two equal doses for the other group. The dosing schedule was delivered at 500mg in the morning and 500mg in the evening for both groups over the entire 21 days.
Although there are several issues with the design of the trial it did provide positive results in the Nicotinamide Riboside group that warrants further exploration in both animal and human models. First, this study showed that there were no toxic events noted at the 1 gram level of Nicotinamide Riboside per day for 21 days. Second, there were multiple inflammatory markers that were decreased in the control group. This shows that Nicotinamide Riboside can decrease inflammation in the body and possibly reduce the signs and symptoms of certain chronic diseases.
Although this was a short duration, small sample size study it was a human study. This is a step in the right direction for NAD+ research and hopefully will spur further research using human models. Understanding the interaction of Nicotinamide Riboside on the interleukin pathways is a fundamental concept that could propel NAD+ into the spotlight. There are many interleukin modulators on the market and each one is expensive. NAD+ may offer a less expensive method that could provide the same or better results than the current pharmaceuticals. Hopefully, more human research studies will be released in the near future with large well designed studies that are tracked over years instead of days.
Since Nicotinamide Riboside is significantly blocked by the liver and very little is allowed to the blood stream using NAD+ or NMN products could provide improved results. Increasing levels of NAD+ is the key to physiological results!

Please note that this study has not been peer reviewed at this time.